144 related articles for article (PubMed ID: 23609193)
1. TL-118-anti-angiogenic treatment in pancreatic cancer: a case report.
Breuer S; Maimon O; Appelbaum L; Peretz T; Hubert A
Med Oncol; 2013; 30(2):585. PubMed ID: 23609193
[TBL] [Abstract][Full Text] [Related]
2. TL-118 and gemcitabine drug combination display therapeutic efficacy in a MYCN amplified orthotopic neuroblastoma murine model--evaluation by MRI.
Komar-Stossel C; Gross E; Dery E; Corchia N; Meir K; Fried I; Abramovitch R
PLoS One; 2014; 9(3):e90224. PubMed ID: 24603724
[TBL] [Abstract][Full Text] [Related]
3. Combination of antiangiogenic therapy using the mTOR-inhibitor everolimus and low-dose chemotherapy for locally advanced and/or metastatic pancreatic cancer: a dose-finding study.
Joka M; Boeck S; Zech CJ; Seufferlein T; Wichert Gv; Licht T; Krause A; Jauch KW; Heinemann V; Bruns CJ
Anticancer Drugs; 2014 Oct; 25(9):1095-101. PubMed ID: 25029236
[TBL] [Abstract][Full Text] [Related]
4. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.
Kozuch P; Grossbard ML; Barzdins A; Araneo M; Robin A; Frager D; Homel P; Marino J; DeGregorio P; Bruckner HW
Oncologist; 2001; 6(6):488-95. PubMed ID: 11743211
[TBL] [Abstract][Full Text] [Related]
5. The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer.
Dineen SP; Sullivan LA; Beck AW; Miller AF; Carbon JG; Mamluk R; Wong H; Brekken RA
BMC Cancer; 2008 Nov; 8():352. PubMed ID: 19038046
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic versus cytotoxic therapeutic approaches in a mouse model of pancreatic cancer: an experimental study with a multitarget tyrosine kinase inhibitor (sunitinib), gemcitabine and radiotherapy.
Casneuf VF; Demetter P; Boterberg T; Delrue L; Peeters M; Van Damme N
Oncol Rep; 2009 Jul; 22(1):105-13. PubMed ID: 19513511
[TBL] [Abstract][Full Text] [Related]
7. Locoregional/systemic chemotherapy of locally advanced/metastasized pancreatic cancer with a combination of mitomycin-C and gemcitabine and simultaneous follow-up by imaging methods and tumor markers.
Klapdor R; Seutter E; Lang-Pölckow EM; Reichle H; Hinrichs A
Anticancer Res; 1999; 19(4A):2459-69. PubMed ID: 10470175
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study.
Petrioli R; Roviello G; Fiaschi AI; Laera L; Marrelli D; Roviello F; Francini E
Cancer Chemother Pharmacol; 2015 Apr; 75(4):683-90. PubMed ID: 25618415
[TBL] [Abstract][Full Text] [Related]
9. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer.
Baker CH; Solorzano CC; Fidler IJ
Cancer Res; 2002 Apr; 62(7):1996-2003. PubMed ID: 11929816
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.
Bruns CJ; Harbison MT; Davis DW; Portera CA; Tsan R; McConkey DJ; Evans DB; Abbruzzese JL; Hicklin DJ; Radinsky R
Clin Cancer Res; 2000 May; 6(5):1936-48. PubMed ID: 10815919
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study).
Heinrich S; Pestalozzi B; Lesurtel M; Berrevoet F; Laurent S; Delpero JR; Raoul JL; Bachellier P; Dufour P; Moehler M; Weber A; Lang H; Rogiers X; Clavien PA
BMC Cancer; 2011 Aug; 11():346. PubMed ID: 21831266
[TBL] [Abstract][Full Text] [Related]
12. [A case of advanced pancreatic cancer successfully treated by combined chemotherapy of S-1 and gemcitabine as second-line chemotherapy].
Kawamoto K; Yamaguchi K; Okabe M; Tsuruta A; Morimoto Y; Niwano M; Sano K; Paku T; Imai S; Yoshida Y; Ito T; Ogasahara K
Gan To Kagaku Ryoho; 2007 Jul; 34(7):1131-4. PubMed ID: 17637556
[TBL] [Abstract][Full Text] [Related]
13. Usage of the NF-kappaB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer.
Müerköster S; Arlt A; Witt M; Gehrz A; Haye S; March C; Grohmann F; Wegehenkel K; Kalthoff H; Fölsch UR; Schäfer H
Int J Cancer; 2003 Apr; 104(4):469-76. PubMed ID: 12584745
[TBL] [Abstract][Full Text] [Related]
14. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial.
Scheithauer W; Schüll B; Ulrich-Pur H; Schmid K; Raderer M; Haider K; Kwasny W; Depisch D; Schneeweiss B; Lang F; Kornek GV
Ann Oncol; 2003 Jan; 14(1):97-104. PubMed ID: 12488300
[TBL] [Abstract][Full Text] [Related]
15. Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growth via anti-angiogenic activities.
Noguchi R; Yoshiji H; Ikenaka Y; Namisaki T; Kitade M; Kaji K; Yoshii J; Yanase K; Yamazaki M; Tsujimoto T; Kawaratani H; Fukui H
Oncol Rep; 2009 Aug; 22(2):355-60. PubMed ID: 19578777
[TBL] [Abstract][Full Text] [Related]
16. The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study.
Watkins DJ; Starling N; Cunningham D; Thomas J; Webb J; Brown G; Barbachano Y; Oates J; Chau I
Eur J Cancer; 2014 May; 50(8):1422-9. PubMed ID: 24613126
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia.
Li Y; Sun J; Jiang Z; Zhang L; Liu G
J Chemother; 2015 Aug; 27(4):227-34. PubMed ID: 25790948
[TBL] [Abstract][Full Text] [Related]
18. The differential effects of metronomic gemcitabine and antiangiogenic treatment in patient-derived xenografts of pancreatic cancer: treatment effects on metabolism, vascular function, cell proliferation, and tumor growth.
Yapp DT; Wong MQ; Kyle AH; Valdez SM; Tso J; Yung A; Kozlowski P; Owen DA; Buczkowski AK; Chung SW; Scudamore CH; Minchinton AI; Ng SS
Angiogenesis; 2016 Apr; 19(2):229-44. PubMed ID: 26961182
[TBL] [Abstract][Full Text] [Related]
19. Pilot study to relate clinical outcome in pancreatic carcinoma and angiogenic plasma factors/circulating mature/progenitor endothelial cells: Preliminary results.
Vizio B; Novarino A; Giacobino A; Cristiano C; Prati A; Brondino G; Ciuffreda L; Bellone G
Cancer Sci; 2010 Nov; 101(11):2448-54. PubMed ID: 20950371
[TBL] [Abstract][Full Text] [Related]
20. S-1 and gemcitabine as an outpatient-based regimen in patients with advanced or metastatic pancreatic cancer.
Kim MK; Lee KH; Jang BI; Kim TN; Eun JR; Bae SH; Ryoo HM; Lee SA; Hyun MS
Jpn J Clin Oncol; 2009 Jan; 39(1):49-53. PubMed ID: 19060295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
